Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin plus gemcitabine vs paclitaxel plus gemcitabine in first-line HER2-negative metastatic breast cancer
KCT0003057Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin, paclitaxel, gemcitabine in breast cancer, sponsored by Eisai Co., Ltd.. Started Dec 2014; status: completed.
02
Drugs
eribulinpaclitaxelgemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0003057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003057.